Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
12 02 2019
Historique:
pubmed: 27 1 2019
medline: 25 6 2019
entrez: 27 1 2019
Statut: ppublish

Résumé

Since the late 1980s, mutations in the

Identifiants

pubmed: 30683722
pii: 1812963116
doi: 10.1073/pnas.1812963116
pmc: PMC6377443
doi:

Substances chimiques

SOS1 Protein 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Banques de données

PDB
['5OVD', '5OVE', '5OVF', '5OVG', '5OVH', '5OVI', '6EIE', '6EPL', '6EPM', '6EPN', '6EPO', '6EPP']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2551-2560

Informations de copyright

Copyright © 2019 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Conflict of interest statement: R.C.H. B.S., J.S., D.M., A.H., C.M.S., N.D.W., H.B., U.B., J.W., V.B., J.M., K.P., G.S., N.B., K.E., K.G., L.W., F.v.N., and B.B. are or have been employees and stockholders of Bayer AG. J.D.K. and D.W. are employees of Evotec AG. R.C.H., B.S., J.S., D.M., H.B., K.P., N.B., K.E., L.W., F.v.N., and B.B. are coauthors of a patent application.

Références

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1761-6
pubmed: 25624485
Angew Chem Int Ed Engl. 2016 Dec 23;55(52):15982-15988
pubmed: 27635522
Nat Rev Drug Discov. 2014 Nov;13(11):828-51
pubmed: 25323927
Genes Cancer. 2011 Mar;2(3):298-305
pubmed: 21779500
Nature. 1982 Jul 22;298(5872):343-7
pubmed: 6283384
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Cell. 2003 Mar 7;112(5):685-95
pubmed: 12628188
Curr Med Chem. 2011;18(7):943-63
pubmed: 21254978
Proc Natl Acad Sci U S A. 1982 Jun;79(11):3637-40
pubmed: 6285355
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Nature. 1998 Jul 23;394(6691):337-43
pubmed: 9690470
J Cell Sci. 2016 Apr 1;129(7):1287-92
pubmed: 26985062
Nat Rev Cancer. 2003 Jan;3(1):11-22
pubmed: 12509763
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Chem Biol. 2014 Dec 18;21(12):1618-28
pubmed: 25455859
Mol Cancer Ther. 2018 May;17(5):1051-1060
pubmed: 29440291
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
Nat Rev Cancer. 2011 Oct 24;11(11):775-91
pubmed: 22020205
Mol Cancer Res. 2015 Sep;13(9):1325-35
pubmed: 26037647
Nat Rev Drug Discov. 2016 Nov;15(11):771-785
pubmed: 27469033
Nat Rev Cancer. 2010 Dec;10(12):842-57
pubmed: 21102635
Cell. 2018 Jan 25;172(3):578-589.e17
pubmed: 29373830
Nature. 2003 Dec 4;426(6966):525-30
pubmed: 14654833
Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
pubmed: 15272157
Science. 2015 Nov 27;350(6264):1096-101
pubmed: 26472758
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3401-6
pubmed: 24550516
Trends Cancer. 2017 Oct;3(10):686-697
pubmed: 28958387
Science. 2016 Feb 5;351(6273):604-8
pubmed: 26841430
Biochemistry. 1997 Mar 25;36(12):3640-4
pubmed: 9132016
Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6140-3
pubmed: 22566140
Nat Chem Biol. 2011 Jul 17;7(9):585-7
pubmed: 21765406
Cancer Discov. 2016 Mar;6(3):316-29
pubmed: 26739882
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
J Biol Chem. 2002 Nov 29;277(48):46265-72
pubmed: 12196540
Cell. 2017 Jun 29;170(1):17-33
pubmed: 28666118
Cancer Cell. 2014 Mar 17;25(3):272-81
pubmed: 24651010
Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16692-7
pubmed: 17075039
Anal Biochem. 2018 May 1;548:44-52
pubmed: 29444450
J Med Chem. 2015 Mar 12;58(5):2265-74
pubmed: 25695162
Nature. 1982 Jun 10;297(5866):474-8
pubmed: 6283357

Auteurs

Roman C Hillig (RC)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany; roman.hillig@bayer.com benjamin.bader@bayer.com.

Brice Sautier (B)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Jens Schroeder (J)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Dieter Moosmayer (D)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

André Hilpmann (A)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Christian M Stegmann (CM)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Nicolas D Werbeck (ND)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Hans Briem (H)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Ulf Boemer (U)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Joerg Weiske (J)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Volker Badock (V)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Julia Mastouri (J)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Kirstin Petersen (K)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Gerhard Siemeister (G)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Jan D Kahmann (JD)

Drug Discovery Services, Evotec AG, 22419 Hamburg, Germany.

Dennis Wegener (D)

Drug Discovery Services, Evotec AG, 22419 Hamburg, Germany.

Niels Böhnke (N)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Knut Eis (K)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Keith Graham (K)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Lars Wortmann (L)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Franz von Nussbaum (F)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.

Benjamin Bader (B)

Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany; roman.hillig@bayer.com benjamin.bader@bayer.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH